Cent Eur J Public Health 2021, 29(1):18-22 | DOI: 10.21101/cejph.a6014

Rubella and tick-borne encephalitis vaccination rates among staff and students at Austrian University of Applied Sciences

Elisabeth Mara, Tamara Kacic, Lisa Zobl, Thomas Pekar
University of Applied Sciences Wiener Neustadt, Wiener Neustadt, Austria

Objectives: Rubella and tick-borne encephalitis (TBE) are infectious diseases caused by viruses. Rubella is an air-borne infection. TBE, on the other hand, is transmitted by virus-infected ticks. Both diseases show specific symptoms after an incubation period of approximately 10 days. The Austrian vaccination plan recommends vaccinations against both viruses, as only these can protect against both infectious diseases. Because of both, an increase in measles infections and the high endemic rate of TBE in Austria, our goal was to evaluate the vaccination rate, antibody titre and general level of knowledge with respect to these two infections amongst adults in order to identify possible nescience regarding booster vaccination and general titre rates.

Methods: One hundred ninety-nine people participated in the study of the TBE and rubella titre determination. We used indirect ELISA and asked the volunteers to complete a questionnaire.

Results: The analysis of the results showed a vaccination coverage rate of over 90% for both diseases.

Conclusion: Our findings lead to the conclusion that the protection through immunization is very high and the vaccines used are extremely effective, particularly as some individuals do not adhere to the recommended vaccination schedule.

Klíčová slova: rubella, tick-borne encephalitis, vaccination, vaccination rate

Vloženo: 23. říjen 2019; Revidováno: 15. leden 2021; Přijato: 15. leden 2021; Zveřejněno: 31. březen 2021  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mara E, Kacic T, Zobl L, Pekar T. Rubella and tick-borne encephalitis vaccination rates among staff and students at Austrian University of Applied Sciences. Cent Eur J Public Health. 2021;29(1):18-22. doi: 10.21101/cejph.a6014. PubMed PMID: 33831282.
Sdílet...
Stáhnout citaci
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobrazit celý článek

    Reference

    1. European Centre for Disease Prevention and Control. Monthly measles and rubella monitoring report - December 2019. Stockholm: ECDC; 2019 Dec.
    2. Duclos P. National Immunization Technical Advisory Groups (NITAGs): guidance for their establishment and strengthening. Vaccine. 2010 Apr 19;28 Suppl 1:A18-25. Přejít k původnímu zdroji... Přejít na PubMed...
    3. Babigumira JB, Morgan I, Levin A. Health economics of rubella: a systematic review to assess the value of rubella vaccination. BMC Public Health. 2013 Apr 29;13:406. doi: 10.1186/1471-2458-13-406. Přejít k původnímu zdroji... Přejít na PubMed...
    4. Federal Ministry Republic of Austria Social Affairs Health Care and Consumer Protection. Tick-borne encephalitis (TBE). In: Federal Ministry Republic of Austria Social Affairs Health Care and Consumer Protection. Austrian Vaccination Plan 2020. Vienna: Federal Ministry Republic of Austria Social Affairs Health Care and Consumer Protection; 2020. p. 19-24. (In German.)
    5. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec. 2011 Jun 10;86(24):241-56. Přejít na PubMed...
    6. Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 2007;25(43):7559-67. Přejít k původnímu zdroji... Přejít na PubMed...
    7. Fafangel M, Cassini A, Colzani E, Klavs I, Grgič Vitek M, Učakar V, et al. Estimating the annual burden of tick-borne encephalitis to inform vaccination policy, Slovenia, 2009 to 2013. Euro Surveill. 2017 Apr 20;22(16):30509. doi: 10.2807/1560-7917.ES.2017.22.16.30509. Přejít k původnímu zdroji... Přejít na PubMed...
    8. Doerr HW, Gerlich WH. Medical virology: basics, diagnostic, prevention and therapy of viral diseases. 2nd ed. Stuttgart, New York: Georg Thieme Verlag; 2010. (In German.)
    9. Hahn H, Kaufmann SHE, Schulz TF, Suerbaum S. Medical microbiology and infectiology. 6th ed. Heidelberg: Springer Medizin Verlag Heidelberg; 2009. (In German.)
    10. Orenstein WA, Cairns L, Hinman A, Nkowane B, Olive JM, Reingold AL. Measles and rubella global strategic plan 2012-2020 midterm review report: background and summary. Vaccine. 2018;36 Suppl 1:A35-A42. Přejít k původnímu zdroji... Přejít na PubMed...
    11. Vynnycky E, Adams EJ, Cutts FT, Reef SE, Navar AM, Simons E, et al. Using seroprevalence and immunisation coverage data to estimate the global burden of congenital rubella syndrome, 1996-2010: a systematic review. PLoS One. 2016 Mar 10;11(3):e0149160. doi: 10.1371/journal.pone.0149160. Přejít k původnímu zdroji... Přejít na PubMed...
    12. Kunz C. TBE vaccination and the Austrian experience. Vaccine Apr 1. 2003;21 Suppl 1:S50-5. Přejít k původnímu zdroji... Přejít na PubMed...
    13. Statistik Austria. Reported cases of notifiable diseases 2017 according to federal states 2018 [Internet]. Vienna: Statistik Austria; c2017 [cited 2021 Jan 15]. Available from: https://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/gesundheitszustand/uebertragbare_krankheiten/022361.html.
    14. McLean HQ, Fiebelkorn AP, Ogee-Nwankwo A, Hao L, Coleman LA, Adebayo A, et al. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults. Vaccine. 2018 Sep 11;36(38):5732-7. Přejít k původnímu zdroji... Přejít na PubMed...
    15. Dimech W, Grangeot-Keros L, Vauloup-Fellous C. Standardization of assays that detect anti-rubella virus IgG antibodies. Clin Microbiol Rev. 2016 Jan;29(1):163-74. Přejít k původnímu zdroji... Přejít na PubMed...
    16. Böttiger M. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine. 1995 Dec;13(18):1759-62. Přejít k původnímu zdroji... Přejít na PubMed...

    Zpět na obsah